Cavitation Technologies, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q4 2025.
-
Symbol
-
CVAT on OTC
-
Location
-
Chatsworth,, CA
-
Fiscal year end
-
30 June
-
Latest financial report
-
17 Feb 2026
Quick Takeaways
- CVAT - Cavitation Technologies, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity 885%.
What Changed
- Return On Equity YoY change: <span class="text-red-600">-606%</span>.
- Most recent SEC facts end date: 13 Feb 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original Filing
Latest SEC snapshot (2026-02-13) highlights Return On Equity 884.9%, Return On Assets -310.2%, and Operating Margin -911.5%.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
25.6/100
Weak
Confidence high
Return On Equity
885%
Metric score 100.0/100
Return On Assets
-310%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.29x
- Quick Ratio
- 0.2x
- Debt to Equity
- -15.32x
Strengths
Return On Equity
Watchpoints
Return On Assets, Operating Margin, and Current Ratio
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
309,720,740
|
+8.9%
|
Q4 2025
|
Q2 2026
|
shares
|
|
Common Stock, Shares, Outstanding
|
309,720,740
|
+8.9%
|
Q4 2025
|
Q2 2026
|
shares
|
|
Common Stock, Value, Issued
|
$310,000
|
+9.2%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
301,177,864
|
+5.9%
|
Q4 2025
|
Q2 2026
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
301,177,864
|
+5.9%
|
Q4 2025
|
Q2 2026
|
shares
|
Additional Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Cost of Revenue
|
$0
|
-100%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Research and Development Expense
|
$82,000
|
+67%
|
Q4 2025
|
Q2 2026
|
USD
|
|
General and Administrative Expense
|
$1,208,000
|
+36%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Operating Income (Loss)
|
$1,185,000
|
-769%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Earnings Per Share, Basic
|
0
|
|
Q4 2025
|
Q2 2026
|
USD/shares
|
|
Earnings Per Share, Diluted
|
0
|
|
Q4 2025
|
Q2 2026
|
USD/shares
|
|
Cash and Cash Equivalents, at Carrying Value
|
$31,000
|
-95%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Accounts Receivable, after Allowance for Credit Loss, Current
|
$0
|
|
Q4 2025
|
Q2 2026
|
USD
|
|
Assets, Current
|
$44,000
|
-94%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Assets
|
$55,000
|
-92%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Liabilities, Current
|
$153,000
|
-75%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Liabilities
|
$303,000
|
-59%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$27,694,000
|
-4.5%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$248,000
|
-978%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Liabilities and Equity
|
$55,000
|
-92%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Common Stock, Shares Authorized
|
1,000,000,000
|
0%
|
Q4 2025
|
Q2 2026
|
shares
|
|
Common Stock, Shares, Issued
|
309,720,740
|
+8.9%
|
Q4 2025
|
Q2 2026
|
shares
|
|
Common Stock, Par or Stated Value Per Share
|
0.001
|
0%
|
Q4 2025
|
Q2 2026
|
USD/shares
|
|
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
|
$31,000
|
-95%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Preferred Stock, Shares Issued
|
0
|
|
Q4 2025
|
Q2 2026
|
shares
|
|
Preferred Stock, Shares Authorized
|
10,000,000
|
0%
|
Q4 2025
|
Q2 2026
|
shares
|
|
Additional Paid in Capital
|
$27,136,000
|
+3.6%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Preferred Stock, Shares Outstanding
|
0
|
|
Q4 2025
|
Q2 2026
|
shares
|
|
Interest Expense
|
$14,000
|
0%
|
Q4 2025
|
Q2 2026
|
USD
|
|
Preferred Stock, Par or Stated Value Per Share
|
0.001
|
0%
|
Q4 2025
|
Q2 2026
|
USD/shares
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets